October 20, 2005
Dougherty Laser Vision Selected for Tetraflex™ IOL Clinical Trial

Practice to Serve as One of Just Five Vision Centers Nationwide to Participate in Phase 3 FDA Study of Next Generation Accommodating Lens

Los Angeles – October 20, 2005 – Dougherty Laser Vision has been selected as one of just five refractive surgery centers in the nation to participate in the Phase 3 FDA clinical study of the new Tetraflex™ accommodating intraocular lens (IOL) implant.

The Tetraflex is designed to provide permanent clear reading, intermediate and distance vision for patients with presbyopia (i.e., age-related loss of zooming power). It represents a significant advancement over earlier generation accommodating lenses in terms of its design and performance. Results from earlier international clinical studies are very promising.

“We are delighted to join such an elite group of top surgery centers to participate in this exciting clinical study,” said Paul Dougherty, M.D. “The Tetraflex lens will help people over age 40 with presbyopia regain the ability to see clearly at a range of distances, while minimizing or virtually eliminating the need for reading glasses.”

The lens implant procedure takes just minutes, and is essentially identical to standard intraocular lens insertion during cataract surgery. The Tetraflex is manufactured by Lenstec (St. Petersburg, FL), which has a long and distinguished history of producing innovative, high quality lenses.